Novartis sickle-cell drug gets U.S. FDA approval
By John Miller and Carl O'Donnell (Reuters) - Novartis AG on Friday won U.S. approval for its experimental sickle cell disease drug, Adakveo, making it the first of several proposed new therapies designed to offer lasting relief for patients with the debilitating blood disease to get U.S. regulatory clearance
By John Miller and Carl O'Donnell
(Reuters) - Novartis AG
The biologic drug, also known as crizanlizumab, was shown in trials in its high-dose formula to cut sickle cell pain crises nearly by half to 1.63 incidents annually from 2.98 in those getting a placebo. The Food and Drug Administration's approval came nearly two months ahead of its due date for a decision in January.
Novartis has forecast that the drug's annual sales will top $1 billion (£781.49 million), much of which will likely come from U.S. government payers such as Medicare and Medicaid.
The drug is the first to offer patients with sickle cell disease targetted relief from pain crises, a common symptom of sickle cell disease, which often also causes swelling, infections, and vision problems. Current treatments, which include blood transfusions, drugs that increase haemoglobin, and pain medicines, only alleviate symptoms as they arise.
Novartis' drug may soon face competition from Voxelotor, a once daily pill developed by Global Blood Therapeutics Inc
Other potential cures for the disease that would alter genetic mutations responsible for blood cell sickling are also undergoing clinical trials run by drugmakers including Bluebird Bio Inc
About 100,000 people in the United States, most of African descent, suffer from the disease in which their red blood cells are sickle-shaped, leading to episodes of intense pain, infections and deadly strokes.
(Reporting by John Miller in Zurich, Carl O'Donnell in New York and Trisha Roy in Bengaluru; Editing by Arun Koyyur and Matthew Lewis)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Guinea president 'captured', govt dissolved, claim army putschists'; attack on presidential palace repulsed, say authorities
Reports suggest that they captured President Alpha Conde and dissolved the government, bust the ground situation remains unclear
NEW YORK (Reuters) -The price of cryptocurrencies plunged and crypto trading was delayed on Tuesday, a day in which El Salvador ran into snags as the first country to adopt bitcoin as legal tender. Shares of blockchain-related firms also fell as crypto stocks were hit by trading platform outages. But the major focus was on El Salvador, where the government had to temporarily unplug a digital wallet to cope with demand.
By Joseph White and Sanjana Shivdas (Reuters) -The head of Apple Inc's car project, Doug Field, is going to work for Ford Motor Co to lead the automaker's advanced technology and embedded systems efforts, a hiring coup for Ford Chief Executive Jim Farley.